New Oral AntiCoagulant Use in REnal Disease and AF (NOACURE-AF) Where do we stand? An expert consensus view using the Delphi method

Çoner, Ali

Journal Metrics

Impact Factor (2022): 0.8
CiteScore (2022): 1.2
Source Normalized Impact
per Paper: 0.22
SCImago Journal Rank: 0.348

52/3Current Issue Ahead of Print Archive Most Accessed Articles

Quick Search

In authors and

In titles and abstracts

In keywords

In all

Archives of the Turkish Society of Cardiology

New Oral AntiCoagulant Use in REnal Disease and AF (NOACURE-AF) Where do we stand? An expert consensus view using the Delphi method [Turk Kardiyol Dern Ars]

Turk Kardiyol Dern Ars. 2021; 49(7): 596-597 | DOI: 10.5543/tkda.2021.21180

New Oral AntiCoagulant Use in REnal Disease and AF (NOACURE-AF) Where do we stand? An expert consensus view using the Delphi method

Ali Çoner
Department of Cardiology, Başkent University Hospital Alanya Application and Research Center, Antalya, Turkey

How to cite this article
Ali Çoner. New Oral AntiCoagulant Use in REnal Disease and AF (NOACURE-AF) Where do we stand? An expert consensus view using the Delphi method. Turk Kardiyol Dern Ars. 2021; 49(7): 596-597

Corresponding Author: Ali Çoner, Türkiye
Manuscript Language: English

TOOLS Full Text PDF Print Download citation RIS EndNote BibTex Medlars Procite Reference Manager Share with email Share Send email to author Similar articles PubMed Google Scholar